TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02914561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Filgotinib tablets administered orally once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once daily.
Study: NCT01009177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 500 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01447160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortisone
Description: intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
Study: NCT01498718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine
Description: VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study: NCT01447160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
Study: NCT04363450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Loading dose of two placebo capsules twice 12 hours apart followed by 1 capsule twice weekly
Study: NCT03294629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensAwake™ modification
Description: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
Study: NCT00412074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU Vitamin D3 (cholecalciferol)
Description: 400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2400 IU Vitamin D3 (cholecalciferol)
Description: 2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6400 IU Vitamin D3 (cholecalciferol)
Description: 6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
Study: NCT02772978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Description: Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
Study: NCT01498718

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study: NCT04439994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: The participant will be given i.d. in 0.1 mL volumes of a hypertonic saline solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: The participant will be given i.d. in 0.1 mL volumes of a saline solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
Study: NCT02068560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dDAVP infusion
Study: NCT04170829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
Study: NCT00876785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bread breakfast
Description: A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wheat bread based breakfast
Description: Reference wheat bread breakfast
Study: NCT01498718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TIV
Description: 2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
Study: NCT02929836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
Study: NCT02991573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceram X

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceram X

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prime & Bond XP
Description: Control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: technique 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: technique 2
Study: NCT03224988

Intervention type: DEVICE
Intervention: TMS
Description: A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.

Intervention type: DEVICE
Intervention: TMS
Description: A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
Study: NCT02932124

Intervention type: DEVICE
Intervention: mechanical chest compression device
Study: NCT04997408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Customized exercise app
Description: A Wearable Device-Based Assisted Post-Stroke Rehabilitation system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person therapist-supervised rehabilitation
Description: In-person therapist-supervised rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person therapist-supervised rehabilitation
Description: In-person therapist-supervised rehabilitation
Study: NCT00091572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
Study: NCT01054118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38431055
Description: Liquid suspension of JNJ-38431055 administered as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Capsule containing 100 mg of sitagliptin administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 + Sitagliptin 100 mg
Description: Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
Study: NCT02929836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LA linear ablation
Description: LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LA linear ablation
Description: LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
Study: NCT00316524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN® (IMVAMUNE)
Description: 1x 10E8_TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN® (IMVAMUNE)
Description: 1x 10E8_TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN® (IMVAMUNE)
Description: 1x 10E8_TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris-Buffer

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tris-Buffer
Study: NCT04212013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibrutinib
Description: Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be similarly dosed at 4 capsules daily.
Study: NCT06450613

Intervention type: DEVICE
Group type: OTHER
Intervention: radiofrequency ablation
Description: HCC Radiofrequency ablation
Study: NCT02929836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFAE ablation
Description: Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
Study: NCT06450613

Intervention type: OTHER
Group type: OTHER
Intervention: percutaneous ethanol injection
Description: HCC percutaneous ethanol injection
Study: NCT03332160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch head and neck lymphedema treatment system
Description: Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard home lymphedema care
Description: May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
Study: NCT02051023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FML 0.1% eyedrops
Description: Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquifilm artificial tears eyedrops
Description: Liquifilm instillation 4 times a day for 22 days
Study: NCT00318331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
Study: NCT01804166

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.

Intervention type: DRUG
Group type: OTHER
Intervention: Golimumab
Description: This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
Study: NCT02037490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grow2Gether
Description: Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person.
Study: NCT04142190

Intervention type: DRUG
Intervention: ELONVA
Description: Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.

Intervention type: DRUG
Intervention: PUREGON
Description: Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
Study: NCT01981889

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
Study: NCT00351273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline and Rifampin
Description: doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin and Rifampin
Description: Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
Study: NCT00351273

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methylcellulose
Study: NCT01926769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03082352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Metoprolol Tablet 100mg
Description: BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaloc Tablet 100mg
Description: Betaloc Tablet 100mg will be used as a comparator drug for the BE study
Study: NCT00137189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resource-oriented music therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Study: NCT00987701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
Study: NCT02900755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
Study: NCT02966015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast test catheter
Description: This is a newly developed catheter
Study: NCT02241187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DW & DCE-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draws
Description: Blood samples will be drawn at various time points.
Study: NCT04064645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of respiratory rate with DUT and comparison with reference
Description: The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation.
Study: NCT03936751

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: This is the standard treatment for OSA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nasal Strips
Description: Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
Study: NCT01054118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension and placebo capsule administered as single doses
Study: NCT05893615

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
Study: NCT02929836

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: linear ablation
Description: Right atrial CTI ablation was performed during SR.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CARTO
Description: 3 dimensional mapping system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CARTO
Description: 3 dimensional mapping system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CARTO
Description: 3 dimensional mapping system